The angiotensin AT 2 receptor (AT 2 R) represents an important component of the renin-angiotensin system since it is involved in the (patho) physiology of different cardiovascular and neuronal diseases. Furthermore, AT 2 receptors can partly mediate beneficial effects of angiotensin AT 1 receptor (AT 1 R) blockers, and direct pharmacological AT 2 receptor agonism emerges as a novel therapeutic strategy. This review discusses the constitutive and ligand-mediated activity as well as the signal transduction of the AT 2 receptor, focusing on adapter proteins which directly bind to this receptor. Direct protein-protein interaction partners of the AT 2 receptor described so far include the transcription factor promyelocytic zinc finger protein, AT 2 receptor binding protein and the AT 1 receptor. In addition, the putative crosstalk of the AT 2 receptor with the renin/ prorenin receptor (RER) via the promyelocytic zinc finger protein (PLZF) and the role of oestrogens on the regulation of the AT 2 receptor are presented. Conceiving the coupling of the AT 2 receptor to different adapter proteins with distinct and partly opposing cellular effects and the implications of its constitutive activity might help to overcome the current controversies on the (patho)physiological role of the AT 2 receptor.
Introduction
The renin-angiotensin system (RAS) represents a crucial system within cardiovascular physiology and pathophysiology, since it is causally involved in a broad spectrum of diseases ranging from arterial hypertension, atherosclerosis, cardiac hypertrophy and diabetic nephropathy to stroke. [1] [2] [3] [4] [5] [6] Furthermore, a plethora of clinical trials demonstrated that blockade of the RAS by angiotensin AT 1 receptor blockers (ARB) or angiotensin-converting enzyme (ACE) inhibitors is able to reduce progression and mortality in patients with heart failure or diabetic nephropathy. 2, 7 Two receptors, the AT 1 receptor and the angiotensin AT 2 receptor, mainly mediate the effects of angiotensin II. Publications of several groups indicate that AT 2 receptor activation can counteract the vasoconstrictory, pro-hypertrophic and pro-proliferative effects of an AT 1 receptor activation. 1, 8, 9 Furthermore, the AT 2 receptor is able to mediate neuronal differentiation in vitro 10, 11 and neuroprotective effects in different models ranging from stroke 12 to central 13 and peripheral 14 nerval injury.
Despite its progressed age -renin was discovered by Tigerstedt in 1898 15 -the RAS has not lost attractiveness; the novel drug class of direct renin inhibitors, represented by the first-in-class drug aliskiren, was launched in 2007. 15 In addition, a human renin/prorenin receptor (RER)also termed (pro)renin receptor or (P)RR -which can specifically bind prorenin and renin, has been cloned recently 16 and might represent a novel pharmacological target based on its involvement in cardiac and renal end-organ damage. 17, 18 As discussed below, there is also a putative regulatory interplay between the AT 2 receptor and the RER, since both share the adapter protein promyelocytic zinc finger protein (PLZF). Finally, the controversies on the (patho)physiological role of the AT 2 receptor are inspiring the RAS research. 19, 20 This article discusses direct protein-protein interaction partners of the AT 2 receptor, i.e., adapter proteins and heterodimers, and the respective implication for cardiovascular (patho)physiology and pharmacology. A second focus is the role of poly(ADP-ribose) polymerase-1 (PARP-1) and related oestrogens on the promoter regulation of the AT 2 receptor gene, which represents a current workscope of our group.
Adapter proteins and promoter regulation of the angiotensin AT 2 receptor -implications for cardiac pathophysiology Signal transduction of AT 2 receptorconstitutive receptor activity The AT 2 receptor belongs to the family of G-protein-coupled receptors containing seven transmembrane domains and shares only 32% amino acid sequence identity with the AT 1 receptor in the rat species. 1, 21 Interestingly, the AT 2 receptor is characterised by some unusual features, such as constitutive receptor activation, i.e., intrinsic activity without ligand binding. This implicates that the AT 2 receptor expression level per se is associated with the level of receptor activation. 21, 22 In general, receptors with a high constitutive activity are characterised by a high basal activity of their effector systems, a marginal response to agonists as well as substantial inhibitory effects of inverse agonists. 23 An unusual receptor function of the AT 2 receptor was already implicated about a decade ago based on the observation that -as opposed to the AT 1 receptor -different angiotensin II analogues affected binding to the AT 2 receptor to nearly similar extents, suggesting that the AT 2 receptor pharmacophore is very distinct from the AT 1 receptor pharmacophore and that no single interaction is critical for binding to the AT 2 receptor. 24 These results are also consistent with a model in which the native AT 2 receptor is already in an active state. Subsequent work demonstrated that the AT 2 receptor can generate a signal cascade driving apoptosis even in the absence of angiotensin II in vitro. 25 Furthermore, this AT 2 receptor-induced apoptosis is not further enhanced by angiotensin II at least in fibroblasts and vascular smooth muscle cells used in the respective study. 25 In addition, apoptosis of vascular smooth muscle cells was not inhibited by the AT 2 receptor antagonist PD123319. In this context, it is important to note that several cell culture-related parameters such as confluence, passage, starving conditions and stripping protocols affect AT 2 receptor transcription or expression thereby creating putative bias. [25] [26] [27] [28] Furthermore -beyond the controversy on the 'good' or 'evil' role of an AT 2 receptor activation (see below) -it was reported that the overexpression of the AT 2 receptor alone caused a hypertrophy of isolated cardiomyocytes which was unaffected by angiotensin II stimulation or the antagonist PD123319. 29 Recently, it was demonstrated that homooligomers of the AT 2 receptor -formed by intermolecular disulphide bonds -can stimulate cell signalling without ligand stimulation, providing mechanistic insights into the constitutive activity of this receptor. 30 Constitutive activity of the AT 2 receptor does not exclude the possibility that the AT 2 receptor is also activated by ligands. Miura and Karnik proposed an interesting model in which ligandindependent effects are mediated by p38 mitogen-activated protein kinase (MAPK) and caspase 3, whereas angiotensin II-dependent effects are imparted by p42/p44 MAPK. 25 Apart from its constitutive activity, the AT 2 receptor -compared to the AT 1 receptor -exhibits a slower angiotensin II-induced internalisation not involving b-arrestin. 31, 32 Furthermore, AT 2 receptor ligands seem to prevent AT 2 receptor degradation. 33 Signal transduction of AT 2 receptoradapter proteins In our opinion, it is crucial to identify direct physical interaction partners to clearly analyse regulatory cascades and networks, because a pure co-regulation of mRNAs and proteins under certain stimulatory conditions -even in a temporal sequential pattern -is not sufficient to conclude a causal relationship within a signal transduction pathway.
Direct physical protein interaction partners of the AT 2 receptor described so far include the following (figure 1):
(1) In 1996 it was shown that the AT 2 receptor couples to both Gai2 and Gai3, thereby demonstrating that this receptor is G-protein coupled. 34 Later on, it was observed that the activation of the Gai subunit requires the Gbg subunit. 35 Nevertheless, data indicate that angiotensin II binding to the AT 2 receptor was not altered by G-protein binding to the receptor. This is indicative for an atypical role of G-proteins in AT 2 receptor function, 21 since the ternary complex formed by the agonist, the G-protein-coupled receptor and the G-protein is normally characterised by a high agonist affinity. 23 (2) Senbonmatsu et al. identified the transcription factor PLZF as a protein which can directly interact with the C-terminal intracellular part of the AT 2 receptor. 32 This interaction was revealed by a yeast two-hybrid screening of a human heart library and confirmed by an affinity column binding assay. PLZF, which is disrupted in patients with translocation t(11;17)(q23;q21)-associated acute promyelocytic leukaemia, is a multiple zinc finger-containing DNA-binding protein implicated in transcriptional repression and also transcriptional activation. 36, 37 The authors showed that PLZF can bind to and activate the promoter of the regulatory subunit p85a of the phosphatidylinositol-3 kinase (PI3K) (PI3K-p85a), causing an increase in PI3K-p85a protein level which was associated with an increase in protein synthesis and with growth promotion of cardiomyocytes. 32 In this context it is important to note that PI3K-p85a phosphatidylinositol-3 kinase depends on growth factors, such as epidermal growth factor, fibroblast growth factor or insulin-like growth factor, for its activation, 31, 32 indicating that AT 2 receptor alone is not responsible for the observed effects on cardiomyocytes. In addition, the authors showed that an interaction of the AT 2 receptor with Gi is involved in the AT 2 receptor-PLZF interplay and the subsequent nuclear translocation of PLZF, linking G-proteins and PLZF. 32 (3) Furthermore, it was shown that the AT 2 R receptor physically associates with SH2 domain-containing phosphatase 1 (SHP-1). 38 SHP-1 association with the AT 2 receptor and SHP-1 activation required the presence of Gas alone, rather than the Gabg heterotrimer, consistent with the atypical role of G-proteins in AT 2 receptor function discussed above. SHP-1 in turn decreases cellular tyrosine phosphorylation. 21 In this context, it has been shown that AT 2 receptor stimulationinvolving activation of different phosphatases such as SHP-1 and MKP-1 -is able to inhibit MAPK activity which is related to the antiproliferative effects of the AT 2 receptor. 1, 2, 19 The inhibitory effect of the AT 2 receptor on MAPKs depends on the proliferation status of the cellular system used and was also observed in vivo using transgenic mice. 19 In addition, AT 2 receptor activation can also inhibit the JAK-STAT pathway through which certain cytokines and growth factors mediate their effects. 19 (4) Our group was able to identify the AT 2 R binding protein (ATBP) as a novel protein that can bind to the cytoplasmic C-terminus of the AT 2 receptor. 39 This interaction between the AT 2 receptor and ATBP was detected by a yeast two-hybrid screening using a mouse embryo library as a prey and verified by coimmunoprecipitation (CoIP). ATBP is expressed in at least three different isoforms termed ATBP50, ATBP60 and ATBP135. 39 ATBP50, also termed ATIP1, is the major isoform since it was initially identified by the yeast two-hybrid screenings, 39, 40 is expressed ubiquitously 39, 41 and constitutes the most abundant isoform e.g. in brain, heart, breast and ovary. 41 ATBP50 plays a crucial role concerning the transport of the AT 2 receptor from the Golgi compartment to the cell membrane, mediates the inhibitory effects on MAPKs and also the antiproliferative effects of the AT 2 receptor in N1E-115 neuroblastoma cells. 39 On the other hand, AT 2 receptor activation increases ATBP50 mRNA levels, indicating a positive feedback loop. 39 Consistently, the ATBP mRNA expression in AT 2 receptor knockout mice was reduced to 10% compared to wild-type mice. 38 Our results concerning ATBP were confirmed by two independent groups who cloned ATBP-analogous proteins termed AT 2 receptor interacting protein or ATIP 40 and mitochondrial tumour suppressor gene 1 or MTSG, 42 respectively. In addition, our observations regarding the functional role of ATBP -i.e., a protein necessary for transport as well as function of the AT 2 receptor -are consistent with two recent publications. Work of de Godoy and Rattan indicates that the externalisation of the AT 2 receptor from an intracellular localisation to the plasma membrane may be responsible for receptor activation 43 which is consistent with observations of Miura et al.
suggesting that AT 2 receptor translocation in the cell membrane is necessary for cell signalling. 30 Apart from the signal transduction cascades downstream of the AT 2 receptor linked to direct physical interactions, our group was able to show that AT 2 receptor activation regulates the mRNA level of the zinc finger homoeodomain enhancerbinding protein (Zfhep). 44 In addition, it is established that bradykinin, NO and cGMP mediate effects of the AT 2 receptor such as vasodilatation. [45] [46] [47] Furthermore, AT 2 receptor stimulation can induce the generation of ceramides in neuronal cells. 48 Signal transduction of AT 2 receptorputative crosstalk with the RER As already mentioned in the introduction, there might be a crosstalk between the AT 2 receptor and the recently cloned RER based on the finding that PLZF is an adapter protein of both receptors.
Renin and prorenin are classically regarded as (pro)enzymes, but cloning of the RER has broadened this view. The RER is expressed in, for example, brain, heart, kidney, liver and pancreas 16, 49 and exerts a dual function: 16 Our group could identify the transcription factor PLZF as a direct protein interaction partner of the C-terminal domain of the RER by yeast twohybrid screening and coimmunoprecipitation. 36 Upon activation of the RER by renin, PLZF is translocated into the nucleus, represses transcription of the RER itself, thereby creating a very short negative feedback loop, but activates transcription of PI3K-p85a. SiRNA against the RER abolished these effects. A PLZF cis-element in the RER promoter was identified by site-directed mutagenesis and electrophoretic mobility shift assay. Consistently, renin stimulation caused a 6-fold increased recruitment of PLZF to this promoter region as shown by chromatin-immunoprecipitation (ChIP). 36 Moreover, renin stimulation of rat H9c2 cardiomyoblasts induced an increase of cell number and a decrease of apoptosis. These effects were partly abolished by PI3K inhibition and completely abrogated by siRNA against PLZF. 36 Consistently, PI3K-p85a and also PLZF are known to be involved in stimulation of protein synthesis and cardiac hypertrophy. 32, 50 Finally, mRNA expression analysis in PLZF knockout mice confirmed the role of PLZF as an upstream regulator of RER and PI3K-p85a. 36 Recently, we were able to demonstrate that, apart from renin, prorenin is also capable of inducing the RER-PLZF-PI3K signal transduction pathway. 51 The RER exerts a crucial role in cardio vas cular end-organ damages. A decoy peptide corresponding to the handle region of prorenin, which competitively inhibits prorenin binding to its receptor, attenuated the development and progression of hypertension-induced cardiac fibrosis, 17, 52 and also completely inhibited the development of diabetic nephropathy in different rat models. 18, 53 The beneficial effects of a prorenin receptor blockage by these decoys on left ventricular mass in spontaneously hypertensive rats (SHR) were recently demonstrated by an independent group. 54 What are the putative interactions between the RER and the AT 2 receptor? First, angiotensin II-dependent interactions are likely, since binding of (pro)renin to the RER increases the enzymatic activity of the local RAS, thereby providing more angiotensin II for the AT 2 receptor.
Secondly, by sharing PLZF as adapter protein, there might be an angiotensin II-independent crosstalk between the signal transduction cascades of both receptors. It is even conceivable that AT 2 receptor activation reduces the amount of PLZF available at the RER -i.e., that there is a competition between both receptors for PLZFthereby inhibiting the detrimental cardiovascular effects of a RER activation. Furthermore, ternary or quaternary complexes consisting of AT 2 receptor, PLZF and RER can be envisaged. Signal transduction of AT 2 receptorcrosstalk with the AT 1 receptor AT 1 receptor and AT 2 receptor interact at the gene regulation level. AT 1 receptor activation enhances AT 2 receptor mRNA degradation, whereas AT 2 receptor activation increases AT 2 receptor mRNA transcription 9,55 ( figure 2 ). On the other hand, AT 1 receptor expression is increased on mRNA and protein level in the aorta from AT 2 receptor knockout mice 56 and transfection of vascular smooth muscle cells with the AT 2 receptor gene results in the decreased expression of AT 1 receptor mRNA and protein, 57 indicating a reciprocal crosstalk between these two receptors. Furthermore, it was shown in endothelial cells that an ARB can increase promoter activity and mRNA of the AT 2 receptor. 58 Apart from this interaction between AT 1 receptors and AT 2 receptors regarding the gene regulation level, there is also a functional interaction on the ligand level. There is evidence that the presence of ARBs causes an increased activation of the AT 2 receptor by angiotensin II which contributes to the beneficial effects of these substances on blood pressure and cardiovascular remodelling.
Since AT 1 receptor blockade interrupts the negative feedback of angiotensin II on renin release, treatment with ARBs will lead to pronounced increases in plasma, and possibly also tissue angiotensin II levels 3 (figure 2). Because this angiotensin II cannot bind to the blocked AT 1 receptors, it stimulates unopposed AT 2 receptors.
Regarding end-organ damage, in 1997 it was already shown in a rat heart failure model that the beneficial effects of AT 1 receptor antagonism with respect to left ventricular end-diastolic volume and cardiac hypertrophy are triggered by AT 2 receptor activation, since AT 2 receptor antagonism with PD123319 reversed these changes (so-called 'PD reversal'). 59 Aortic banding experiments have shown that the inhibitory effect of valsartan on coronary arterial thickening and perivascular fibrosis is weaker in AT 2 receptor knockout mice compared to wild-type mice, indicating that the beneficial valsartan effects are also mediated by AT 2 receptor stimulation. 60 In addition, Xu et al.
were able to demonstrate that valsartan -in contrast to an ACE inhibitor -increased cardiac function and decreased cardiac interstitial collagen deposition after induction of myocardial infarction (MI) to a greater extent in wild-type mice compared to AT 2 receptor knockout mice, supporting the hypothesis that the cardioprotective effects of ARBs are partially mediated by AT 2 receptor activation. 61 Interestingly, deletion of the AT 2 receptor per se had no effect on basal cardiac 61 indicating that AT 2 receptor function might be linked to ARB therapy, a condition in which angiotensin II levels are increased. Furthermore, we have shown that AT 2 receptors are involved in the regulation of the Na + -HCO 3 symporter-1 in the infarcted myocardium. 62 With respect to ARB treatment, this finding suggests that these drugs shift post-MI recovery in ischaemia-mediated myocardial acidosis from a sodium-hydrogen exchanger-mediated to a more NBC-1-mediated mechanism of alkalinisation by engaging the AT 2 R, thereby protecting the heart against arrhythmias. The antihypertensive effect of AT 1 receptor antagonists may also be partially mediated by the AT 2 receptor. AT 2 receptor knockout mice exhibit an increased vasopressor response to angiotensin II. 63, 64 Furthermore, one of the two initial knockout models also shows a mild hypertensive phenotype. 64 Conversely, the AT 1 receptor-mediated pressor effect of angiotensin II infusion is abolished in transgenic mice overexpressing the AT 2 receptor in vascular smooth muscle cells. 65 Consistently, it was shown that infusion of antisense oligodeoxynucleotides directed against the AT 2 receptor into renal interstitium caused an increase in systemic blood pressure. 66 In addition, co-infusion of the AT 2 receptor antagonist PD123319 with angiotensin II causes a higher increase in blood pressure in rats on high salt diet compared to angiotensin II infusion alone. 67 In a further study it was shown that AT 2 receptor activation contributes to blood pressure-lowering effects of ARBs in normotensive rats but not in SHRs. 68 Nevertheless, with respect to the most relevant species, forearm vascular resistance during angiotensin II infusion in elderly women taking candesartan was elevated by the AT 2 receptor antagonist PD123319 compared to placebo. 69 
Modulation of AT 2 receptor function by oestrogens
The beneficial effects of oestrogens or an additional X-chromosome on the cardiovascular system are well established. 70, 71 Oestrogens seem to modify the proportion of AT 1 receptors relative to AT 2 receptors in favour of AT 2 receptors. [72] [73] [74] Moreover, it was shown that a genetic polymorphism in the 3'-untranslated region of the AT 2 receptor gene only modulates the left ventricular mass index in female but not in male patients with hypertrophic cardiomyopathy. 75 Another study indicated that an exonic AT 2 receptor polymorphism was associated with hypertension in women but not in men. 76 Therefore, we have analysed the oestrogen-induced regulation of the AT 2 receptor and its interaction partner ATBP/ATIP.
Our data indicate that oestradiol stimulation experiments using oestrogen receptor a overexpression are prone to artefacts due to effects on the vector backbone of luciferase reporter plasmids. 77 Concerning the oestrogen-responsive gene trefoil factor 1, we unexpectedly observed that a decrease in trefoil factor 1 promotor activity can be used as a positive control for oestrogen effects. 77 Furthermore, several parameters such as cell type-specificity, confluence, passage, species, stripping protocols, oestradiol dosage and oestradiol incubation time modulate the effect of oestradiol on AT 2 receptor promoter activity and AT 2 receptor mRNA level. 77 Oestradiol effects on human AT 2 receptor and human ATIP mRNA levels seem to be constrained to an early time-point. Consistently, we were not able to observe clear gender-specific expression differences of these genes in murine and human heart, but large interindividual variabilities. 77 Putative gender and oestradiol effects under pathophysiological conditions are under investigation.
Nevertheless, during our project examining the effects of oestrogens on the gene regulation of AT 2 receptor and ATBP, a fascinating paper was published. The authors demonstrated that a transient, site-specific, double-stranded DNA break formation occurs in the promoter region during signal-dependent activation of gene transcription, 78 a phenomenon called 'promoter cleavage'. 79 The complex, which is responsible for this novel mode of gene regulation, comprises topoisomerase IIb, PARP-1 and oestrogen receptor a among others. Promoter cleavage by this complex is a prerequisite for oestrogen-dependent transcription of the pS2 gene. In addition to pS2, recruitment of topoisomerase IIb and PARP-1 as well as promoter cleavage upon gene activation were observed for other promoters such as PSA and MMP12, indicating the generality of this phenomenon. In conclusion, PARP-1 is a major mediator of oestrogen effects. Therefore, we hypothesised that PARP-1 might also regulate AT 2 receptor and ATBP genes independent of oestrogens. The respective results as well as the role of PARP-1 in cardiovascular medicine are discussed in the next section.
Signal transduction of AT 2 receptorthe role of PARP PARP-1 is a ubiquitous nuclear protein catalysing the attachment of poly(ADP-ribose) polymers to several different acceptor proteins such as histones, RNA polymerase II, p53 and PARP itself. [80] [81] [82] PARP-1 is involved in a broad spectrum of pathophysiologies such as necrosis, apoptosis, [83] [84] [85] In addition, PARP-1 seems to play a role in learning and memory. 86 PARP-1 can act as a transcriptional co-activator, but also as a repressor. 82, 85, 87, 88 Consistently, a microarray analysis of fibroblasts derived from PARP knockout mice indicated that the expression of some genes is increased while the expression of others is repressed. 89 PARP-1 affects transcription in the absence of DNA damage due to several different mechanisms ranging from direct sequence-specific DNA binding, via recruitment by transcription factors to poly(ADPribosyl)ation of other transcription factors and histones. PARP's enzymatic activity is required for its transcriptional regulatory functions in some contexts but not in others. 82, 87, 88 Consistent with the dual role of PARP-1 as transcriptional activator and repressor, PARP-1 can promote chromatin decondensation as well as condensation. 86 The important role of PARP concerning the basal transcription has been known since 1983 when the identity of transcription factor IIC with PARP was shown. 90 In addition, RNA polymerase II can serve as a substrate of the poly(ADP-ribosyl)ation reaction, and PARP can enhance transcription by acting during preinitiation complex formation. 87 Regarding the RAS, interactions with PARP have been described. Angiotensin II can contribute to the generation of superoxide and peroxynitrite via AT 1 receptors. These reactive molecules can cause DNA-strand breakage which in turn is a trigger for PARP activation. 85, 91 Furthermore, PARP-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. 92 Consistently, PARP activation was demonstrated in human failing heart with NYHA class III-IV. 93 PARP also represents a target in cardiovascular drug development. Different PARP inhibitors such as 3-aminobenzamide and INO-1001 were able to reduce myocardial necrosis, to decrease cardiac infarct size, to improve myocardial contractility and to increase survival in diverse animal models ranging from MI and aortic banding to diabetic cardiomyopathy. 85 Additionally, INO-1001 from Inotek is already in clinical phase II for MI. 94 Consistent with all these findings, recently published data of our group (Reinemund J. et al, 2008 , Biochem. Pharmacol. 77: 1795 -1805 indicate that PARP-1 is also a major transcriptional regulator of AT 2 receptor and ATBP genes on promoter and transcript level in vitro as well as in vivo.
Conclusions
Publications from different groups have been able to demonstrate that AT 2 receptor activation is beneficial with respect to the cardiovascular system. 1, 3, 9 Using microvascular coronary endothelial cells, our group was able to demonstrate for the first time that the AT 2 receptor exerts antiproliferative effects. 8 Growth-potentiating effects of the AT 2 receptor antagonist PD123319, i.e., growth inhibitory effects of AT 2 receptor itself, were observed in different in vivo models ranging from neointima formation and atherosclerosis to cardiac and renal fibrosis. 19 Furthermore, transgenic overexpression of the AT 2 receptor in the heart preserves cardiac function after MI. 95 Consistently, AT 2 receptor overexpression by lentiviral gene transfer into the left ventricle of SHRs decreased left ventricular wall thickness. 96 A similar study demonstrated that intracardiac, lentiviral vector-mediated gene transfer attenuates cardiac hypertrophy and fibrosis in Sprague-Dawley rats subjected to an angiotensin II infusion. 97 Finally, our group recently demonstrated that the novel AT 2 receptor agonist compound 21 exerts strong cardioprotective effects in a MI model. 98 In this context, it is of interest to note that AT 2 receptors are expressed in a small portion of cardiomyocytes and that the upregulation of this receptor after MI involves cell types other than cardiomyocytes. 99 However, apart from these beneficial functions of the AT 2 receptor, there is also experimental evidence that AT 2 receptor stimulation can promote fibrosis and growth. AT 2 receptor activation in AT 2 receptor-transfected smooth muscle cells stimulated collagen synthesis, 100 and blockade of the AT 2 receptor in angiotensin II-induced hypertensive rats reduced aortic fibrosis. 101 In addition, ventricular hypertrophy induced by pressure overload was not observed in AT 2 receptor knockout mice, 102 and increased AT 2 receptor expression results in angiotensin II-independent hypertrophy of cardiomyocytes. 29 Finally, some AT 2 receptor knockout models indicate that the AT 2 receptor can mediate left ventricular hypertrophy as well as cardiac and perivascular fibrosis. 102, 103 Apart from these 'good' or 'evil' effects, some publications indicate that there is no influence of AT 2 receptors on cardiac hypertrophy, i.e., a neutral role of the AT 2 receptors. Using SHRs treated with the ARB candesartan alone or in combination with the AT 2 receptor antagonist PD123319, it was demonstrated that AT 2 receptors contribute to the antifibrotic but not antihypertrophic effects of ARBs. wild-type and AT 2 receptor-knockout mice subjected to aortic banding concerning the reduction of cardiac growth. 60 The same study also observed that aortic banding per se caused cardiac hypertrophy to a similar degree in wild-type and knockout mice. Finally, angiotensin II infusion resulted in a comparable cardiac hypertrophyassessed by myocyte cross-sectional area, left ventricular mass and atrial natriuretic peptide mRNA levels -in wild-type mice and transgenics overexpressing the AT 2 receptor, whereas cardiac perivascular fibrosis was reduced by stimulation of AT 2 receptors. 104, 105 In human clinical cardiovascular trials, no data on AT 2 receptor function (e.g. mRNA quantification in different organs or effects of simultaneous AT 2 receptor blockade) have been obtained. Therefore, it is difficult to assess the putative concordance between animal data and the bedside. Concerning human studies in general, forearm vascular resistance during angiotensin II infusion in elderly women taking candesartan -which unmasks a vasodilator response to angiotensin II in forearm resistance vessels -was elevated by the AT 2 receptor antagonist PD123319 compared to placebo, suggesting vasodilatory actions of the AT 2 receptor. 74 Consistently, vasorelaxation mediated by the AT 2 receptor was demonstrated in isolated human coronary microarteries using myography. 106 Furthermore, an upregulation of AT 2 receptors in the human species can be observed under pathological conditions such as skin injury ex vivo 107 and heart failure in vivo. 108 The discrepancies concerning the functional role of the AT 2 receptor discussed above may also be resolved by a model in which not the receptor per se is 'good' or 'evil', but in which the type of adapter protein recruited to the receptor determines the cellular effects (figures 1 and 2). In this context, it should be mentioned that PLZF -apart from the functions described above -can also exert antiproliferative and pro-apoptotic functions. 37 ,109 Furthermore, the cellular effects of PLZF are modulated by the presence or absence of growth factors as discussed above and illustrated in figure 2. Concerning 'membrane' adapters of the AT 2 receptor, AT 1 receptor-AT 2 receptor heterodimers have been described which antagonise the AT 1 receptor function 110 ( figure 2 ). In addition, the fine-tuned and regulated expression ratio between AT 1 receptor and AT 2 receptor, as well as of other modulators of cellular growth, influences the cellular outcome of AT 2 receptor activation. 111 The transformation of this 'adapter' hypothesis into definite knowledge is a difficult task and could involve time-resolved tandem affinity purification in combination with different knockout / knockin models and siRNA approaches under different (patho)physiological conditions. This model in which the type of adapter protein recruited to the AT 2 receptor determines the nature of the signal transduction cascade corresponds to a so-called multiple-state receptor model with several activated states R* 1 , R* 2 , R* 3 etc., in contrast to the classical two-state model. 22, 112 The multiple-state model also implies that some ligands may specifically activate one or another signalling mechanism of the same receptor, a phenomenon called biased agonism, ligand-directed signalling or agonist (-receptor) trafficking. 113 Therefore, it could be possible to develop receptor-specific drugs with pathway-selective activities. This possibility should be considered when discussing the impressive effects of the novel AT 2 receptor agonist compound 21. 98, 114 The function of the AT 2 receptor strongly affects the efficacy of RAS target inhibition. ACE inhibitors and renin inhibitors would benefit from 'negative' AT 2 R effects, whereas ARBs would benefit from 'positive' AT 2 R effects. Therefore, from a biased marketing perspective 'old' arguments favouring ACE inhibitors can now be applied to aliskiren. The recent ONTARGET study seems not to support a major role of the AT 2 receptor in reducing cardiovascular risk. 115 But also aliskiren might suffer from caveats such as increased renin plasma levels, treatment escape and missing long-term mortality studies, as discussed recently. 51, 116 We are optimistic that the 'true' human pathophysiological contribution of the AT 2 receptor will be clarified in phase I/II trials with compound 21. Considering the different AT 2 receptor adapter proteins and the putative biased agonism phenomenon, direct agonism at the AT 2 receptor could cause greater effects than stimulation with the endogenous ligand angiotensin II. 
Consistently, valsartan was equally effective in

